Teva Pharmaceutical Industries Limited (TEVA) Launches SYNCare™ Home Administration Support Program For Patients On SYNRIBO® (Omacetaxine Mepesuccinate) For Injection
9/3/2014 9:06:22 AM
FRAZER, Pa.--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced the launch of SYNCareTM, a comprehensive program designed to support patients taking SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, at home. Through the SYNCare program, patients will receive: home delivery of prepared, prescribed doses; all supplies needed for home administration; educational resources and injection training support; and a 24/7 toll-free hotline number. SYNRIBO® was recently approved by the U.S. Food and Drug Administration (FDA) for home administration. Adults with chronic or accelerated phase chronic myeloid leukemia (CML) who are no longer responding to, or who could not tolerate, two or more tyrosine kinase inhibitors (TKIs) now have the option of administering SYNRIBO® therapy at home.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by